Tools   Select Another Resource Report Type

http://www.alzheimer-europe.org/

A non-governmental organization aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.

Proper citation: Alzheimer Europe (RRID:SCR_003802) Copy   

•   Source: SciCrunch Registry

http://www.remynd.com/

Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

Proper citation: reMYND (RRID:SCR_003824) Copy   

•   Source: SciCrunch Registry

http://www.amorfix.com/

Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc.

Proper citation: Amorfix (RRID:SCR_003783) Copy   

•   Source: SciCrunch Registry

http://www.orion.fi/en/

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

Proper citation: Orion (RRID:SCR_003911) Copy   

•   Source: SciCrunch Registry

http://www.icdd-sas.com/

A contract research organization (CRO) that are mitochondrial experts, operating mitochondrial function screening platforms by using accepted pharmaceutical innovative technologies. The dynamic analysis of several typical markers of central and mitochondrial metabolism, redox status, or mitochondrial biogenesis are included in the determination of bioenergetic balance in living cells of human origin. These platforms are used to validate the activity of pharmaceuticals, cosmetics and environmental assets xenobiotics on mitochondrial targets associated with the activity or toxicity of these products under the selected models. They specialize in the selection of drugs affecting the progression of neurodegenerative diseases and offer proven models of Huntington's disease, Parkinson's and Alzheimer's, using primary cells of human origin. They have developed and use technology cellulomique and proteomics to identify early response profiles and clinical safety of pharmaceutical products for diseases of the CNS.

Proper citation: Innovative Concepts in Drug Development (RRID:SCR_003940) Copy   

•   Source: SciCrunch Registry

http://www.alzheimer-hellas.gr/english.php

A non-profit organization whose aim is to offer advice concerning the care of Alzheimer''''s disease patients, information and services for the people affected and their families. Also, to offer mutual help to the family members of the patients in order to reduce the social, economic and emotional cost deriving from the long care of people suffering from dementia. Lastly, the association attempts to publicize the social needs of the population affected and to inform the public in order to be acquainted with the problem. The mission of the Greek Association of Alzheimer''''s Disease is * the early diagnosis of dementia by scientists * the promotion of research * education and training for all the stakeholders * the development of Care Units for patients with Alzheimer''''s Disease * the provision of useful information and advise (24 hour help-line) on dementia problems (caring, legal or financial issues) * the presentation of lectures by health professionals and informal carers, covering all aspects of Alzheimer Disease * and the development of professional seminars during the whole year.

Proper citation: Greek Association of Alzheimers Disease and Related Disorders (RRID:SCR_003938) Copy   

•   Source: SciCrunch Registry

http://www.eisai.com/

A global pharmaceutical company.

Proper citation: Eisai (RRID:SCR_003936) Copy   

•   Source: SciCrunch Registry

http://www.fondation-alzheimer.org/

A non-profit registered French charity that provides a research on Alzheimer's disease and related disorders program with the following goals: * create a dynamic national and international collaborative research of the fundamental absorptions, * densify the network of public and private researchers with an attractive policy * install infrastructure basic, clinical and laboratory performing research * promote interaction with the health industries to reduce development time. At the national level the Foundation has implemented measures Research Plan, through: * animation fabric French medical and scientific research, * coordination of research initiatives * the implementation of actions, * support for specific projects. Internationally, the Foundation is at the origin of an international mobilization of researchers, initiated during the French Presidency of the European Union. Called Joint Programming, this pilot initiative involves 23 countries will coordinate their efforts at European level research on neurodegenerative diseases, especially Alzheimer's disease.

Proper citation: Alzheimer's Plan Foundation (RRID:SCR_004032) Copy   

•   Source: SciCrunch Registry

http://www.proteomics.com/

Commercial company delivering content for personalized medicine in the areas of Biomarker Services, Biomarker Assays, Isobaric and Isotopic Reagents and Proprietary Biomarkers. A global leader in applied proteomics, they use high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases) and to develop rapid assays for testing. The biomarkers discovered in body fluids or tissues are validated, developed and commercialized as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

Proper citation: Proteome Sciences (RRID:SCR_004106) Copy   

•   Source: SciCrunch Registry

http://www.Ablynx.com

A biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases including inflammation, hematology, oncology and pulmonary disease.

Proper citation: Ablynx (RRID:SCR_002940) Copy   

•   Source: SciCrunch Registry

http://www.mrc-cbu.cam.ac.uk/Imaging

Portal where neuroimaging studies are carried out using a Siemens 3T Tim Trio Magnetic Resonance Imaging (or MRI) scanner that is wholly dedicated to studies in Cognitive Neuroscience. From emotions and memories to language and learning, functional neuroimaging is being applied in many different areas of Cognitive Neuroscience. In many cases, this research relies upon support from healthy volunteers although neuroimaging studies are also being conducted in various clinical populations, including depression, anxiety, Parkinson's disease and Alzheimer's disease.

Proper citation: CBU Imaging Wiki (RRID:SCR_003014) Copy   

•   Source: SciCrunch Registry

http://adni-info.org/

Database of the results of the ADNI study. ADNI is an initiative to develop biomarker-based methods to detect and track the progression of Alzheimer's disease (AD) that provides access to qualified scientists to their database of imaging, clinical, genomic, and biomarker data.

Proper citation: ADNI - Alzheimer's Disease Neuroimaging Initiative (RRID:SCR_003007) Copy   

•   Source: SciCrunch Registry

http://www.stereologyresourcecenter.com/

A company of professionally trained stereologists, bioscientists, computer engineers, educators, and support personnel that provides comprehensive neurostereology products and services to the global bioscience community. These products and services include: stereology and image analysis software, digital imaging technology, turnkey stereologer solutions, comprehensive stereology and image analysis/image processing software, professional contract services, neurostereology workshops, basic stereology courses, and online stereology webinars. The Center also offers tissue processing (sectioning, staining, slide preparation) and stereology data collection services. Researchers may use equipment and facilities to complete projects with full confidentiality and according to Good Laboratory Practices guidelines.

Proper citation: Stereology Resource Center (RRID:SCR_003137) Copy   

•   Source: SciCrunch Registry

http://www.alzheimer.ca/

A nonprofit health organization that works to improve the quality of life of Canadians affected by Alzheimer's disease and other dementias. This organization also supports research on the cause and potential cures for the disease through education and funding.

Proper citation: Alzheimer Society of Canada (RRID:SCR_000485) Copy   

•   Source: SciCrunch Registry

http://www.bu.edu/alzresearch/about/cores/neuro.html

The Neuropathology Core leads neuropathological analyses of brains donated by research registry participants of the Boston University Alzheimer's Disease Center. The Core works with the Clinical Core to carry out the Brain Tissue Donation Program, which provides brain tissue for analyses that will help to understand the underlying pathology of AD. The Core also works closely with the Data Management and Statistics Core to maintain a comprehensive computerized database of information resulting from neuropathological analyses. The Boston University Brain Bank of the Neuropathology Core documents neuropathological findings of Center research registry participants, but also of brain donors from important related BUSM studies such as the Framingham Heart Study and the Centenarian Study.

Proper citation: Boston University Alzheimer's Disease Center Neuropathology Core Facility (RRID:SCR_000513) Copy   

•   Source: SciCrunch Registry

http://www.heptares.com/

A drug discovery company focused on small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. They are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilization, structure determination, and fragment-based discovery. Their partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Their objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, ADHD and chronic migraine.

Proper citation: Heptares Therapeutics (RRID:SCR_000499) Copy   

•   Source: SciCrunch Registry

http://www.alzprotect.com/en/

Commercial organization that develops drug candidates in the field of neurodegenerative diseases and particularly Alzheimer's. Their main objective is the development of a drug against Alzheimer's disease from molecules patented by Inserm and the University of Lille II.

Proper citation: AlzProtect (RRID:SCR_000492) Copy   

•   Source: SciCrunch Registry

https://www.nih.gov/research-training/accelerating-medicines-partnership-amp

Partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical companies and non-profit organizations whose goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. The group explores three major areas of disease: diabetes, Alzheimer's disease, and rheumatoid arthritis and lupus.

Proper citation: Accelerating Medicines Partnership (RRID:SCR_014927) Copy   

•   Source: SciCrunch Registry

http://www.brain.northwestern.edu/research/for-researchers/index.html

Tissue bank for collecting, cataloging and storing postmortem brain tissue samples from subjects with and without neurological disorders. Specimens are available for research on cognitive impairment, Alzheimer's, dementia and other disorders along with clinical data such as demographic information, health and family history and neuropsychological test scores. The bank provides services to distribute postmortem brain tissue and other samples to investigators for use in research that will provide qualitative and quantitative diagnostic information to physicians, families, and researchers.

Proper citation: Northwestern CNADC Tissue Bank / Neuropathology Core (RRID:SCR_013178) Copy   

•   Source: SciCrunch Registry

http://brain.ubc.ca/

Research facility for research on neurological and psychiatric disorders on the learning brain and the aging brain. The Centre utilizes a multidisciplinary approach to explore the causes and potential treatments of disorders like Alzheimer's disease, mental health and addiction, stroke and neurotrauma. The Centre focuses on translating research into patient care and therapies.

Proper citation: Djavad Mowafaghian Centre for Brain Health (RRID:SCR_013149) Copy   

•   Source: SciCrunch Registry